Results 151 to 160 of about 4,268 (199)
Journal of Antimicrobial Chemotherapy, 2021 International audienceAbstract Background Multivariable baseline factor analysis across cabotegravir\mkern1mu+\mkern1murilpivirine clinical trials showed that HIV-1 subtypes A6/A1 and the presence of rilpivirine resistance-associated mutations (RAMs ...
Sidonie Lambert-Niclot +2 more
exaly +2 more sources
Design and Testing of a Cabotegravir Implant for HIV Prevention
Journal of Controlled Release, 2021 Long-acting antiretroviral implants could help protect high-risk individuals from HIV infection. We describe the design and testing of a long-acting reservoir subcutaneous implant capable of releasing cabotegravir for several months. We compressed cabotegravir and excipients into cylindrical pellets and heat-sealed them in tubing composed of ...
Thomas J Hope +2 more
exaly +4 more sources
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
Antimicrobial Agents and Chemotherapy, 2017 Drug-drug interactions between antiretroviral medications and rifampin complicate the treatment of HIV and tuberculosis coinfection. This study evaluated the effect of rifampin on the pharmacokinetics of oral cabotegravir, an integrase strand transfer ...
Y. Lou +7 more
exaly +2 more sources
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. [PDF]
Clinical Infectious DiseasesBackground: Obesity is increasingly prevalent among people with human immunodeficiency virus (HIV, PWH). Obesity can reduce drug exposure; however, limited data are available for long-acting (LA) antiretrovirals.
Catia Marzolini +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cabotegravir and rilpivirine for the treatment of HIV
Expert Review of Anti-infective Therapy, 2020Introduction: Antiretroviral treatment (ART) has led to improved control of HIV infection, giving the opportunity of exploring therapeutic alternatives as new long-acting (LA) regimens, that might improve the quality of life of people living with HIV (PLWH).Areas covered: This article overviews the pharmacokinetic and pharmacodynamic properties of LA ...
David Rial-Crestelo +2 more
openaire +2 more sources
Formulary Drug Review: Cabotegravir
Hospital Pharmacy, 2021Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-
Terri L. Levien +2 more
openaire +1 more source
An evaluation of cabotegravir for HIV treatment and prevention
Expert Opinion on Pharmacotherapy, 2020Introduction: Oral pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) represent the cornerstones of HIV infection prevention and treatment. However, despite their high efficacy, the need to take daily oral pill(s) negatively impacts long-term patient adherence.
Canetti D., Spagnuolo V.
openaire +2 more sources